Articles
20.11.2019
When to get scientific advice

Discussing the benefits of seeking early scientific advice and what companies need to take into cons...

Read more
Articles
13.11.2019
Medical device market access

What are the pro’s and cons of seeking NICE approval using the Medical Technologies Evaluation Pro...

Read more
Articles
17.10.2019
An analysis of the top 20 most expensive drugs

This study investigates costs of gene/acute therapies versus chronic treatments for rare diseases, o...

Read more
Articles
11.10.2019
EUnetHTAs joint assessment facilitating HTA

How to create, facilitate, and promote sustainable Health Technology Assessment (HTA) cooperation in...

Read more
Articles
03.10.2019
Pricing and market access launch excellence

This study aims to understand the industry perspective on drivers and challenges for a successful la...

Read more
Articles
26.09.2019
New reference pricing rules for Greece 2019

Medicine prices in Greece are set by the IRP. IRP is the process of using the prices in other countr...

Read more
Articles
13.09.2019
Evidence base for Yescarta and Kymriah

Is the evidence base for high-cost CAR T-cell therapies Kymriah and Yescarta sufficient to be grante...

Read more
Articles
04.09.2019
Gene therapies and Managed Entry Agreements

Zolgensma launched in May 2019 in the US for $2.1 million, whilst Zynteglo was launched in the EU in...

Read more
Articles
04.09.2019
Are access agreements essential for NICE access

This study aimed to compare the use of financial agreements for oncology and non-oncology appraisals...

Read more
Articles
13.08.2019
Is market access for oncology treatments easier in

This study from 2017 - 2019 compares the outcomes for oncology and non-oncology appraisals conducted...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.